- Open Access
Mechanically produced schistosomula as a higher-throughput tools for phenotypic pre-screening in drug sensitivity assays: current research and future trends
Biomarker Researchvolume 4, Article number: 21 (2016)
It is crucial to develop new antischistosomal drugs since there is no vaccine and the whole world is relying on only a single drug for the treatment of schistosomiasis. One of the obstacles to the development of drugs is the absence of the high throughput objective screening methods to assess drug compounds efficacy. Thus for identification of new drug compounds candidates, fast and accurate in vitro assays are unavoidable and more research efforts in the field of drug discovery can target schistosomula. This review presents a substantial overview of the present state of in vitro drug sensitivity assays developed so far for the determination of anti-schistosomula activity of drug compounds, natural products and derivatives using newly transformed schistosomula (NTS). It highlights some of the challenges involved in in vitro compound screening using NTS and the way forward.
Hundreds of millions of people are living at risk of schistosomiasis infection . More than 207 million people are infected worldwide with 85% living in Africa. This makes schistosomiasis one of the most devastating tropical diseases in the world and remains a major source of morbidity and mortality for developing countries, especially in Sub-Saharan Africa . Also known as “snail fever”, schistosomiasis is a water-borne trematodiasis carried by fresh water snails infected with one of the five varieties of the parasite Schistosoma. But three principal varieties are mainly the causative agents for human schistosomiasis: Schistosoma mansoni, Schistosoma haematobium and Schistosoma japonicum. The pathophysiology associated with schistosomiasis, is mainly due to immune response to the schistosome eggs that are trapped in tissues and organs. The liver, intestines and bladder usually trap eggs on their way out of the host. The spleen, as a lymphoid organ, becomes enlarged (splenomegaly) and together with the enlargement of the liver result in hepatosplenomegaly. Schistosomiasis has both an acute and a chronic phase. Acute schistosomiasis are generally short-term and mild and can develop a few weeks after the schistosome parasite first penetrates into the skin of the host. But if left untreated, schistosomiasis cause by any of the three species listed above may become a chronic inflammation which develops slowly into swelling, fibrosis and necrosis of the affected tissues such as intestinal organs, the liver and the bladder, as well as a wide range of other symptoms which gradually damage the host physiologically and even cognitively [2, 3].
Mass drug administration (MDA) in endemic areas using praziquantel (PZQ) remains a major cornerstone of schistosomiasis control programs . Praziquantel was discovered in the year 1970’s and brought to the market in 1988 under the name Biltricide [5, 6]. It is so far the only drug available and recommended by World Health Organization (WHO) for the treatment of schistosomiasis. This single drug PZQ, is used for the treatment of millions of people annually and as stated in the recent publications, its coverage is projected to reach 235 million people by 2018, which raises concerns of increasing drug pressure [7, 8]. Furthermore, although there are several advantages of this drug, in particular its high efficacy on the adult worms of all the medically important Schistosoma species and its excellent tolerability, PZQ has some disadvantages, mostly its inefficiency against younger stage of schistosomes . This mean that treatment does not rule out all the worms in those who are infected and necessitates the repeat of the treatment. Again, reliance on a single drug as the sole treatment, while positively reducing morbidity has led to big concerns over development of potential drug resistance . These facts emphasize the imperative to search for the next generation of antischistosomal drugs. Therefore, a number of studies have recommended repeatedly the need for novel drugs, since the drug discovery and development pipeline is virtually dry . Only a few candidates compounds have been studied in preclinical phases  and none of them have reached the clinical trials phase. For instance, the target product profile for a new antischistosomal drug  was not met by mefloquine and artemisinins [13, 14].
Formerly, procedures established at TDR-designated compound screening centers relied on adult worms incubated with the candidate drugs for 72 h . Following the incubation period, the parasite viability was assessed microscopically . This approach of in vitro drug screening based on the phenotype of the whole adult worm organism usually requires the intensive use of laboratory animals (hamster, rats, mice) since there is no existing in vitro life cycles for Schistosoma. This approach is also time consuming and low-throughput and relied on a small number of research groups experts that are able to handle the complex life cycle of Schistosoma and work with both high recovery of adult parasite from mammalian host and long screen timelines. The latter is the consequence of the long period that Schistosoma infection requires to become obvious since in the mouse model, it may take not less than 30 days for S. mansoni infections to become patent  and even more than 30 days for others specie such as S. haematobium.
Not long ago, the screening method using Newly Transformed Schistosomula (NTS) has been popularised as a higher-throughput [17–20]. Here, we have provided an overview for the alternative approach to phenotypic screening younger parasites that can be easily obtained from the intermediary host snails and in greater numbers than adult worms. This review presents the current state of in vitro drug sensitivity assays developed so far for the determination of anti-schistosomula activity of drug compounds, natural products and derivatives using NTS and highlights some of the challenges involved in in vitro compound screening using NTS.
In which stage of the Schistosoma life cycle is schistosomula found?
Schistosomes have a complex life cycle (Fig. 1). The transmission of schistosomiasis occurs when people harboring the parasite contaminate freshwater sources (lakes, ponds, rivers and dams) inhabited by snails with their urine (for urogenital Schistosomiasis) or faeces (for intestinal schistosomiasis) containing parasite eggs. Under optimal conditions the fertilized eggs hatch in water and miracidia are released. Once released from the eggs, miracidia swim in the fresh water and penetrate specific intermediate snail hosts. In the snail host, the miracidiae multiply by asexual division of 2 generations of sporocysts (primary and then secondary sporocysts) and produce cercariae from 4 to 6 weeks [21, 22]. Upon release from the snail, the infective cercariae can remain infective in freshwater for 1 to 3 days . They swim in the water in search of the definitive host. Upon contact with the host, cercariae penetrate the skin of the host, and lose their bifurcated tail to become schistosomulae . It takes several days for the schistomules to move from the skin into the venous circulation then into the lungs . This path generally takes within 5 to 7 days after penetration. The schistosomulae takes at least 15 days to travel through the circulatory system to the hepatoportal circulation where they grow and mature into adult worms and pair up. In humans, adult worms are found to reside in either the perivesicular or mesenteric venules in various locations. This seems to be specific for each species. Specifically, S. japonicum occurs frequently in the superior mesenteric veins draining the small intestine while S. mansoni is frequently found in the superior mesenteric veins draining the large intestine. Nevertheless, S. japonicum and S. mansoni can occupy either location, and they are capable of moving between both sites, therefore it is impossible to state unequivocally that one species is specifically found in one location. Generally, S. haematobium is found in the venous plexus of the bladder, but can sometime be found in the rectal venules. The females start laying eggs from 4 to 6 weeks after infection in their final infection site which is either the bladder or the intestine. This usually continues for 3 to 5 years equivalent to the lifespan of the worm . Eggs are laid in the small venules of the portal and perivesical systems. For S. mansoni and S. japonicum, eggs gradually move towards the lumen of the intestine and of the bladder and ureters for S. haematobium, and are excreted from the body through feces or urine, respectively . The intermediate host snails are primary for transmission, and human contact with fresh water that harbors the infective larval form of the parasite known as cercariae is thus necessary for Schistosome infection .
Importance of in vitro drug screening using Newly Transformed Schistosomula (NTS)
The in vitro culture techniques were developed for parasites after the successful establishment of the life cycle of S. mansoni in the laboratory . The process relied on adult worms incubated with the candidate drugs for 72 h after which the viability of the parasite is microscopically assessed . This approach of phenotypic screening using whole worm organism requires the intensive use of laboratory animals such as hamster, rats and mice since currently there is no existing in vitro procedure to generate adult worms. Moreover, this method is time consuming and low-throughput. It is no wonder that, in the recent years, researchers are using the Newly Transformed Schistosomula (NTS) as a tools for higher-throughput screening for drug sensitivity assay in the field of antischistosomals drug discovrey [12, 17–20, 23–27].
The era of working with schistosomula began with the recovery of mature schistosmulae from the lungs of infected laboratory animals. This was associated with the inconvenience of recovering only limited worm . The transformation of cercariae into schistosomula using simple techniques as centrifugation, repeated aspiration through a syringe needle or chemical stimulation was an important discovery in the field of schistosome cultivation. Nowadays, researchers use cercariae as the starting material for in vitro studies of schistosomes as large numbers of schistosomula can be easily obtained in a manner which is advantageous in economical point of view [18, 19]. Furthermore and most importantly, the use of mechanically transformed schistosomulae limits and replaces the use of live animals in accordance with the 3Rs (reduce, replace, refine) principles of animal protection. Using an artificially produced schistosomula in in vitro drug sensitivity assays might serve as pre-screen tools.
Changes associated with cercariae/schistosomulum transformation
Schistosoma infection occurs when people get in contact with free-swimming larval forms of the parasite (cercariae) released by freshwater snails. Cercariae, with the aid of its tail swim in the water until they penetrate the skin of the definitive host during contact with the contaminated water. From its intermediate snail host to the definitive host (human), the cercariae undergoes a series of adaptive changes. All these changes are known as transformation. During the transformation process, the tail of cercariae is lost and the secretory glands release two substances: a mucus which promotes attachment to the skin and enzymes which degrade the skin . Moreover, on the surface of schistosomula, appears the transient microvilli and a double unit membrane is formed on the tegument . Concurrently, some of the glycocalyx is lost . McLaren and Hockley reported that in vivo, microvilli are developed on the surface of schistosomula obtained throughout penetration of the host skin. This also occurs on schistosomula which have penetrated a mouse skin prepared in vitro and on artificial schistosomula prepared by mechanical separation of the tail from the head of the cercariae . From their investigation, they reported that microvilli occur at approximately the same time, have about the same life-span and show identical morphological characteristics in each of the three types of schistosomula .
Schistosomules rapidly undergo marked physiological and ultrastructural changes in the body of the definitive host in order to adapt to the host’s internal environment . Some of these changes are loss of the glycocalyx, conversion of trilaminate to heptalaminate tegumental membrane , sensitivity of schistosomula to water (loss of water tolerance) , and evacuation of secretory glands. All these changes result in the schistosomulum stage. Transformation is complete within about 2–3 h [30, 32]. Brink et al. published in 1977 a study conducted to compare schistosomula produced artificially and schistosomula recovered after cercariae had penetrated isolated skin . They concluded that the schistosomula prepared by mechanical separation of the tail from the head of the cercariae fulfill the main criteria of transformation from cercarial to schistosomulum. This is justified by the fact that, the surface membrane of all type of schistosomula (those mechanically obtained and those recovered after cercarial penetration of the isolated skin) had changed from trilaminate to heptalaminate structures and had loss their cercarial glycocalyx within 2 h of transformation . They also reported that in vitro, the development of mechanical transformed schistosomules is similar to schistosomula obtained after cercarial had penetrated isolated skin although only 25–50% of mechanically transformed schistosomules reached the ‘gut-closed’ stage by day 12, while 50–70% of skin transformed schistosomules reached this stage . Thus, 2 mains criteria were generated by the authors to help decide whether transformation from cercariae to schistosomula has been effective. The 2 criteria were, the NTS must have developed heptalaminate surface membranes and they must be capable to growth and develop in vitro, at least to the ‘gut-closed’ stage .
Requirement for in vitro drug screening using NTS
Drugs and chemicals
Praziquantel, mefloquine, auranofin, artesunate, metrifonate, oxamniquine, artemisinins, arthemeter are drugs used as antischistosomal compounds. These drugs are usually dissolved in dimethylsulphoxide (DMSO) to obtain drug stock solutions of 10 mg/ml or 10 mM and then diluted into culture media to serve as positive control [12, 20, 23, 25, 26, 34]. The highest concentration of DMSO used as drug solvent should not exceed 1% [15, 18, 24, 34].
Antifungal drug (Amphotericin B) and antibiotic drugs (penicillin 100 to 300 U/ml and streptomycin 100 to 300 μg/ml) are used to supplement the medium in order to avoid fungal and bacteria contamination during schistosomula culture [12, 17, 23, 25–27, 34].
Different type of media such as Basch Medium 169 [18–20, 26, 27, 35, 36], Earles’Minimum Essential Medium [32, 33], Dulbecco’s Modified Eagle’s Medium (DMEM) [17, 19, 26, 31, 35, 37], Minimum Essential Medium (MEM) [19, 27, 35], Roswell Park Memorial Institute (RPMI 1640) [18, 31, 32, 38] and Medium 199 [12, 19, 23–26, 34, 35] have been used in different studies. Other investigations were developed to compare and obtain optimal culture conditions for the NTS. For the optimal culture condition for schistosomula, several studies have shown that the supplemented medium is appropriate. Different concentrations of heat inactivated fetal calf serum (iFCS) 1% , 5% [12, 20, 23, 25–27, 34, 38], 10% [17, 37], or heat inactivated fetal bovine serum (FBS) 5% , 10%  have been used.
The supplemented medium 199 turned out to be the most suitable medium for the incubation of schistosomula and thus has been widely used for in vitro screening of others compounds with known activities against Schistosoma newly transformed schistosomula [12, 23–25, 34]. Thus 5 to 10% heat inactivated calf serum is the commonly used supplement by several researchers.
Snails and cercariae
The snails might be of the genus Bulinus which serves as the intermediate hosts of S. haematobium as well as of S. intercalatum or the genus Biomphalaria or Oncomelania for S. mansoni and S. japonicum respectively. Snails are individually infected with an average of 10 miracidia per snail . In our laboratory, an average of 5 can be used to successfully infect snails. Usually, snails are kept in aquarium with dechlorinated water in a humid room simulating a 12 h day and night cycle. Intermediate host snails start shedding cercariae from 4 to 6 weeks post-infection with miracidia. According to the circadian rhythm, each snail species are then collected and placed individually into 24 or 48 well plates or in a test tube (1 ml of distilled or dechlorinated tap water/well or per tube). Each test tube or well plate can be exposed to artificial light for 30 min , 1 h , or 2 h [40–43]. The cercarial suspension is then collected, cleaned and concentrated by allowing to stand on ice for 30 to 60 min. During this time, cercariae form into a mass, settle and adhere to the bottom of the tube. The supernatant is poured off and replaced with ice-cold distilled water. This suspension is used for the preparation of schistosomula. There are several techniques for transforming cercariae into schistosomula and maintaining them [18, 33, 44–46]. Some of these techniques are performed in vivo and others in vitro. In vivo transformation occurs after host skin penetration  and in vitro transformation can be obtained when parasites penetrate excised skin [33, 47] or when cercariae tails are removed mechanically [12, 18–20, 23–25, 27, 33, 34, 45] or chemically  and cercariae bodies are incubated in physiological media (Fig. 2).
Newly transformed schistosomula (NTS)
In vitro transformation of Schistosome cercariae to schistosomula and maintenance
As the schistosomulum stage is becoming attractive for search of new antischistosomal drugs, this requires the development of efficient, reproducible and rapid means to generate large and suitable quantities of the biological material. The artificial transformation of cercariae into schistosomula can be induced by various effectors for instance the cell growth media at 37 °C [48, 49] or low osmolarity phosphate buffer saline solution  that seem to be able to start off the transformation of cercariae into schistosomula. In vitro, schistosomula can be obtained through excised skin preparation or by mechanical separation of the tail from the body of the cercariae 
Excised skin preparation of schistosomula
Schistosomula can be prepared from cercariae of schistosome by allowing them to penetrate excised rat  or mouse  skins into Hanks' Balanced Salt Solution (HBSS). The possibility of contamination by host material and the low yield of produced schistosomula as reported by Brink et al.  make the excised skin penetration technique inappropriate.
Chemical transformation using glucose
The cercarial transformation can be performed using glucose. This is known as chemical transformation which is carried out based on protocol previously described . Briefly, the cercariae suspension is cooled on ice for 30 min to reduce parasite motility. Afterwards, the cercariae suspension is centrifuged for 2 min at 2000 rpm, then resuspended in 5% glucose and incubated for 10 min at 30 °C . The tails are removed from the bodies using the ice purification method as described below.
Mechanical preparation of schistosomula
The mechanical transformation protocol is the most popular method for obtaining artificially transformed schistosomula. This method is applied to freshly shed cercariae and includes centrifugation, passages through an emulsifying needle, or shaking. The separation of cercariae body from tails is usually done by centrifugation in a density gradient followed by incubation of the cercariae heads in culture media at 37 °C. In order to detach the tails from the body, these methods usually incorporate an initial step consisting of agitating the organisms sufficiently. Schistosomules prepared in vitro and incubated at 37 °C gradually undergo morphological and physiological changes . Tucker in 2001  reported that mechanically transformed schistosmula by 24 h in culture, resemble in most respects cercariae that have penetrated and resided in the skin for about 1 h. Thus, parasites obtained following this protocol is morphologically or biochemically closed enough to those recovered from natural infections [33, 48]. This makes the mechanical transformation the best alternative method for large production of schistosomula for high-throughput studies such as gene expression, identification of drug targets and identification of effective drugs against schistosmes .
In this paper, we will describe the two of the three mechanical methods that have been employed for the acquisition of schistosomules. These include centrifugation, vortexing, or pressure shearing, such as using the 18-, 20-, 21-, 22-gauge–needle method [31, 37, 43–45]. The double-ended–needle method that presumably was developed recently, from the normal needle process seems to be the most widely used for cercariae transformation in vitro [31, 35, 37, 38, 43, 44].
In vitro transformation of cercariae to schistosomula by vortexing
The transformation of cercariae to schistosomula by vortexing is performed based on a protocol of Ramalho-Pinto . Many laboratories used a slightly adapted Ramalho-Pinto method [19, 26]. Briefly, cercarial suspension is cooled on ice for 10 min , 30–40 min [26, 31] in order to reduce parasite motility. Then cercariae are further concentrated by centrifuging for 15 s at 1000 rpm , 2 min at 100 × g , 3 min at 3000 rpm , 4 °C. The supernatant is discarded and the cercarial pellet is resuspended in cold Hanks` Balanced Salt Solution (HBSS) containing or not penicillin-streptomycin and amphotericin B [18, 26], or in 4 °C DMEM or RPMI 1640 . The suspension is vigorously vortexed for 2 min , 4 min , or 45 s twice separated by ice cooling for 3 min  in order to start off tail loss. This step is repeated after an incubation of the mixed tail-schistosomula suspension for 20 min at 37 °C . Tucker  recommended addition of antibiotics if incubation following the transformation will be longer than 8 to 12 h.
In vitro transformation of cercariae to schistosomula by needle and syringe
Using a needle and syringe to separate the tails from the head of cercariae is an equally valid method for the initial phase of preparing schistosomula. In this case, cercarial suspension is placed into a plastic centrifuge tube and a syringe with 18-, 20-, 21-, or 22-gauge–needle is filled. The cercarial suspension is repeatedly passed through the needle (10–20 times back and forth) [31, 38, 43–45].
For the double-ended–needle method, an 18-, 20-, 21-, or 22- gauge double-hub, emulsifying needle with a stabilizing bar is fitted to a sterile 10 ml syringe . Cercariae are drawn up using a second 10 ml syringe which is fitted to the open end of the emulsifying needle. The cercariae tails are sheared by approximately 10–20 passes back and forth through the needle [31, 37, 38]. This procedure involves manipulation of thousands of cercariae which is an obvious biohazard. Therefore mandate the use of protective clothing and gloves, including protection for the face and the eyes. Afterwards, the schistosomule bodies are isolated from the sheared tails by Percoll gradient centrifugation  or another purification method as described below. Table 1 compare the different schistosomula preparation procedure with advantages and disadvantages.
Purification of newly transformed schistosomula (NTS)
The schistosomule bodies can be isolated from the sheared tails by three purification methods which are Percoll, ice and swirling method.
The Percoll method is based on the method of Lazdins et al. . The separation of the bodies from the tails is done on a 70% Percoll gradient (polyvinylpyrolidone-coated colloidal silica particles) by centrifuging for 15 min at 500 × g, 4 °C . After centrifugation, the sample is collected from the bottom of the tube and the collected fraction is then diluted to the culture medium (RPMI 1640, DMEM, Medium 199, 169, MEM, etc…) and centrifuged [31, 37, 38]. The schistomula pellet is resuspended in fresh, warm supplemented medium.
Another purification method of schistosomula is a swirling technique which is a simple and easy. This method was described previously [31, 38]. In this case, schistosomula suspension is poured into a Petri dish with a sufficient warm medium such as 199 , 37 °C RPMI 1640 complete media  or incomplete medium 169 . By swirling the dish gently, all the bodies are settled in the centre and the lighter tails can be aspirated and the bodies are left accumulated in the centre. The bodies (schistosomulae) will be further transferred into 15 or 50 ml centrifuge tubes. This step (swirling and collecting) is repeated until schistosomula are no longer present in the center of the dish. This objective can be reached approximately after 4 to 5 times  or 10 times .
For the ice method, 7 ml of cold HBSS is added to the schistosomula suspension and cooled on ice for 7 min. The supernatant is decanted, and the pellet resuspended again in 7 ml of cold HBSS. This step is repeated three times. The pellet that contained the recovered schistosomula is then resuspended in pre-warmed (37 °C) supplemented Medium 199  or Basch medium .
The obtained purified schistosomula are kept in the schistosmula culture medium and incubate at an atmosphere of 37 °C of 5% CO2 for further experiments.
After the purification, the transformation rate and the purification factor can be estimated. The rate of transformation is estimated by counting the total number of cercariae in the HBSS suspension before transformation, and placing them in relation to the total number of schistosomulae obtained after purification . Marxer et al.  reported a transformation mean rate of 69% for five identically performed mechanical transformations by vortexing and 34% for the chemical transformation.
To estimate the purification factor, the total number of bodies and tails are counted in a sample of 50 μl after the experiment. The ratio is expressed as purification factor. Marxer et al.  after performing the three purification methods, they calculated the mean purification factor for each of the methods. The best purification method according to their analysis is Percoll with purification factor of 24.4 ± 11.4 . This method was followed by the swirling method with a purification factor of 11.7 ± 3.2 . The ice method presenting a very weak mean purification factor of 3 ± 1.7 .
Schistosomula culture and culture media
Techniques required to cultivate parasites in vitro is a major area of concern among present day researchers. Aside the dynamic study and understanding the physiology, behavior and metabolism of parasites, the nature of the antigenic molecules found in their excretory and secretory products need to be vigorously pursued and analyzed upon a successful establishment of the in vitro culture of the parasite. However, this is a difficult task since parasites have complex life-cycles comprising different stages and host species requirements. A good mention is in the case of parasitic helminths. Techniques involved in parasites culture requires knowledge of all types of microbiological cultures as different parasites demands particular culturing conditions such as nutrients, temperature and even incubation conditions.
Cultivation of parasites has immense usefulness in the production of vaccines, testing efficacy of vaccine, and production of antigens for obtaining serological reagents, detection of drug-resistance, screening of potential therapeutic agents and conducting epidemiological studies. Parasite cultivation is always a challenge. In the case of schistosoma, transformed schistosomula can be grown and maintained in vitro in a complex medium . The growing rate of schistosomules cultured in vitro is not the same as those in a permissive host, nor will they become patent adults. Using good and appropriate methods, about 50% of the cultured parasites will mature with fully formed guts, and 10% will develop into sexually distinct male and female worms . Starting with good number of parasites, a good amount of worms can be easily maintained and provide a vast quantity of parasite material for assay. There is also a possibility to increase the percentage of schistosomules forming guts and growing properly (50% versus 20%). This can be achieved by supplementing the growth media with conditioned media during the first week of culture . Using the method described by Tucker et al.  with supplemented DMEM or RPMI1640 media, Schistosoma spp. schistosomules can be grown in culture media for at least two months. Abdulla et al.  noted that the Basch Medium 169 is chosen over RPMI for schistosomula culture since worms survive more in the Bash Medium with 10% mortality for up to 4 weeks whereas in RPMI medium, an average of 40 to 60% of the parasites die within 3 days with continued mortality up to two weeks . Keiser in 2010 reported that schistosmula can survive for at least 96 h in different culture media such as MEM, DMEM, Basch, or TC 199 . Marxer et al.  showed that supplemented Medium 199 is most suitable for the incubation of schistosomula obtained by transformation in supplemented HBSS. After undertaken comparison study on three culture media (DMEM, Medium 199, Basch medium), they reported that in the supplemented Medium 199, the parasites were still alive after 120 h with an average viability value of 2.5 while all schistosomula died by 72 h in Basch medium and by 144 h in DMEM on the other hand as shown in Fig. 3 . Schistosomules are cultured at 37 °C in a 5% CO2 incubator [12, 17, 20, 23, 25–27, 31, 34, 37, 43, 45, 54]. It was also shown that over the course of one week’s incubation, parasites in Basch Medium 169 appear robust and uniform in shape and appearance. The effects of culture media on the growth of schistosomula are summarized in Table 2.
Although the more suitable medium vary from one study to another, we can observe that studies initiated to screen compound FDA library , Medicines for Malaria Venture (MMV) box compounds , Mefloquine-related Arylmethanols  made used of supplemented Medium 199. Thus the supplemented medium 199 seems to be the most suitable medium for the cultivation of schistosomula and might justify why it has been widely used for in vitro screening of other compounds with known activities against Schistosoma newly transformed schistosomula [12, 23–25, 34].
The biggest obstacle to a successful schistosomules culture is contamination by fungal and bacterial, which is mainly due to the fact that the parasites originate from non-sterile snails. Therefore, the use of antibiotics (Penicillin and Streptomycin) is useful to prevent bacteria growth and amphotericin B, a fungizone that prevent fungal growth. Different concentration as indicated above are used.
In vitro drug sensitivity assays with newly transformed schistosomula
Schistosoma NTS in vitro Assay is obtained using one of the transformation methods already described in this review. The NTS suspension adjusted to a concentration of 100 NTS per 50 μL [12, 25, 26, 34] is then incubated in culture medium at 37 °C, 5% CO2 in ambient air for a minimum of 12 to 24 h to allow maturation or in order to achieve complete transformation into schistosomula before being further processed [12, 17, 20, 23–25, 34]. Other authors incubated NTS suspension just for 1 to 3 h before being used in subsequent experiments [18, 27]. The transformed schistosomula in schistosomula culture medium are then incubated with the test drugs in a 96-well flat bottom plate in duplicate or in triplicate and at least 2 to 3 time at a number of 100 NTS/well [12, 20, 25, 26, 34]. Since drug stock solution is prepared in DMSO, the highest concentration of DMSO diluted in Schistosomula culture medium is used to serve as control. Thereafter, drug effects are assessed microscopically under an inverted microscope.
Determination of schistosomula viability in response to test compound
Based on microscope readouts, phenotypic changes of NTS is recorded at 3 different time points (24 h, 48 h, 72 h post-drug exposure). The changes are recorded with regard to death of worms, changes in motility, viability and morphological alterations [12, 25, 34]. This makes use of a viability scale from 0 to 3 (3 = motile, no changes to morphology; 2 = reduced motility and/or some damage to tegument noted; 1 = severe reduction to motility and/or damage to tegument observed; 0 = dead) [12, 13, 25–27, 34]. The 50% (IC50) and/or 99% (IC99) inhibitory concentration are determine for active compounds [12, 23–26, 34].
Inconvenience of microscopic read-out and development of automated technologies
Current methods utilized to assess schistosomula viability encompass microscopic techniques. In this case, the experimenter manipulates the parasite in vitro and assesses the effect of such manipulation by bright field examination of morphology. This procedure has been used in several drug screening protocols [18, 25–27] and general manipulations of parasite development . Schistosome viability has been assessed in various research work using different criteria. Some of the criteria are intracellular granularity, schistosomula movement, schistosomula shape alterations. Nevertheless, evaluating parasite viability through microscopic read-out are itself potential deterrents to the development of high throughput since these methods are slow and subjective and therefore represent a bottleneck for high-throughput screening. More often, high throughput methods are dependent upon assay miniaturisation, objectivity and very demanding in term of quantification. Several complementary techniques initially developed for single cell eukaryotes viability measurement have been adapted to multicellular schistosomes parasites. Among the existing viability assays that have been developed for use with single cell eukaryotes, it is amazing to find that only a limited range of techniques have successfully been translated to studies with schistosomes. This may be explained by the multicellular nature of schistosomes which size more than 1 cm with complex tissue and also its external tegument bound by a heptalaminate membrane . The heptalaminate is thought to be selectively permeable to macromolecules, simple compounds and water . Nonetheless, there is a challenges due to parasite biology, there is also evidence that some techniques developed for single cell viability can successfully be adapted to schistosomes.
The size and complexity of schistosomes can partly be considered as useful attributes for determining viability. One of the valuable trait in assessing schistosome (both schistosomula and adult worm schistosome) viability in vitro is their regular movement, although lack of movement is thought to be not infallible indicator of death. Motility together with other microscopic characteristics such as morphology changes, granularity and tegument damaging [12, 25, 34] are currently the most common indicators for assessing schistosome viability and represent the “gold standard” for assessing drug screening protocols within the schistosomiasis research community [12, 18, 20, 25, 34].
Despite the wide application of bright-field, light microscopic assessment of schistosome viability, this technique presents several problems. Firstly, the personnel should be well trained to acquire sufficient knowledge on diverse schistosome phenotypes. Secondly, the bright-field, light microscopic detection of schistosome viability will always be subjective due to lack of immunological and molecular evidence that death has actually occurred when a schistosome is immobile. Even when the personnel has acquire the proficiency at identifying schistosome phenotypes, this technique is still slow and tedious. For instance a recent study performed the screening of only 640 potential anti-schistosomula compounds per month . Finally, replication of results obtained by bright-field microscopic means is not always possible, because of the absence of uniformity between laboratories. With recent advancements in automated technologies, a number of alternatives read-out assay have been attempted with varying degrees of success in order to avoid the subjective nature of quantifying viability of schistosome from microscopic observation of phenotype alone . For example, methylene blue has shown to stain differentially dead schistosomula and therefore was considered as a reliable dye for dead schistosomula  and has been used to assess the viability of mechanically transformed schistosomula . Regardless, it was thought that vital dyes can be successfully translated from single cell viability markers to multicellular schistosomes.
Some fluorescent compounds such as DNA intercalating dyes, ethidium bromide (EB) and Propidium Iodide (PI) [60, 61], carboxyfluorescein  as well as resazurin have also been used to quantify schistosome viability in low-throughput, microscopic read-out methods. In more detail, resazurin, the active ingredient of Alamar Blue (AB), a non-toxic and cell permeable compound, is blue in color and virtually non-fluorescent. But when resazurin enters the cells, it is converted to resorufin which is red in color and highly fluorescent. Resazurin is continuously reduced to resorufin by viable cells. This staining technique was used to discriminate between live and dead schistosomula after 48 and 72 h of incubation with standard selected drug compounds of known antischistosomal activity . Unfortunately this technique cannot be used for earlier time-points and to measure dose response drug effects .
Ethidium bromide has been used to differentiate dead schistosomula from live ones during microscopic examination , while PI has successfully been used for the same reason (as a differential stain of dead schistosomula) for both microscopic examination and flow cytometry . Carboxyfluorescein in contrast to ethidium bromide and propidium iodide, has been tested as live staining for schistosomula. However, it was difficult to clearly differentiate live schistosomula to dead ones since the latter developed some fluorescence .
By promoting the use of single dye staining, a dual fluorescent viability assay has been developed for schistosomula . In this case, authors combined the use of PI with fluorescein diacetate (FDA) to easily assess the percentage of viable schistosomula present in a sample. By using a microtiter plate reader, this fluorescent bioassay was developed for 96 or 384 well microtiter black-sided, flat-bottom plate optically clear. Ninety-six (96) well plate were designed for medium throughput and 384 for high throughput applications . The use of the fluorescent bioassay has the added advantages that it could increase by 10-fold the number of compounds screened per month over existing microscope methodologies and also, it does not require extensive training of personnel in parasite morphology . Therefore fluorescent bioassay has been shown to be entirely objective  and has been validated with schistosomula. Currently, there are indications that fluorescent bioassay can be adapted for use with adult worm schistosomes as well as other life stages. Although the combined use of PI and FDA, can objectively and rapidly quantify schistosome viability in a high-throughput format, the ability of PI and FDA to provide significant phenotypic data is slightly limited . Therefore, there is still a need for the complementary technologies to the fluorescent bioassay and methodologies that allow the automated assessment of phenotype that could be seen as a great discovery in the field of novel antischistosomal drugs discovery.
Smout et al.  developed a motility assay that was thought to be one of the technological advance to offer a solution to this helminth phenotype quantification challenge, until high content screening as an affordable reality. This assay, which uses the xCELLigence system was a new application or device to monitoring cells in a real-time manner. This was known to simply and objectively assess anthelmintic effects by measuring parasite motility in real time in a fully automated high-throughput fashion. In principle, this technique is based on the detection of changing electrical currents running through mini gold electrodes incorporated into the bottom of tissue culture plates. When schistosomes in the immature and mature stages are quite dense, they usually sediment during in vitro culturing and this make contact with the gold electrodes. It is known that, changes to the culturing conditions that may impact a worm’s physiology will probably modifiy its behavior or phenotype. This result to a measurable fluctuation in current across the electrodes . Since many anti-schistosomal drug compounds act by affecting the motility of the target parasite, the importance of these measurable current fluctuations can be considered as an indicator of potential therapeutic activity. This biophysical characteristic to assess anthelmintic activity of compounds in real time in a high-throughput fashion was demonstrated by Smout et al. . This technology was applied to adult schistosomes to illustrate that by increasing the doses of PZQ, the signal decreased from adult worm schistosomes, and this allowed to generate a dose dependent curve. Can this technology be applied to larval schistosome life stages? Although the answer to this question is currently unknown, it appears feasible. It is believed that this assay may provide an advanced methodology to microscopy that will help remove subjectivity in helminth phenotype characterization as well as making available a technology to compare results directly from different laboratories . But the original cost of the xCELLigence equipment may restrict its widespread use.
Howe et al.  investigated a fluorometric L-lactate assay for viability in schistosoma drug screening assays. Lactate is a by-product of glycolysis. It is secreted via aquaglyceroporins from NTS and adult worm schistosomes . Authors fully investigated parameters of lactate measurement and performed drug sensitivity assays by applying schistosomulae and adult worms to establish a proof of concept. They showed that lactate levels reflect clearly the viability of schistosomula and this was also correlated with schistosomulae numbers. They tested compounds with described potencies, and compared activities of fluorometric L-lactate assay with microscopy. Howe et al.  concluded that lactate can be used as simple surrogate marker since its measurement can be a promising new approach to assess the viability of schistosomulae in drug sensitivity assays. However, this technique requires two things. Firstly, the supernatant must be removing from the drug assay without aspirating the Schistosomula and secondly, the drug assay should be diluted to an acceptable fluorescence range as needed. These two aspects make the fluorometric L-lactate assay less than high-throughput .
More recently, the commercial luminescence-based cell viability kit known as CellTiterGlo® was validated by Lalli et al.  for the in vitro assay using S. mansoni NTS and adult worms schistosomes. In this procedure unfortunately, a precise multi-drop dispenser is required to ensure an exact number of NTS present in each well. Although the investigation of marker-dye based assays has been a popular activity, we can simply note that, the aim of a simple, inexpensive and accurate dye that does not require much additional equipment or analysis has not so far been entirely met . Table 3 summarizes different in vitro drug sensitivity assays developed so far for the determination of anti-schistosomula activity of drug compounds. The summary of publications cited in this review are contained in Table 4.
One of the great deal of new drug discovery against schistosomes is dependent on in vitro whole parasite screens. Access to adequate quantities and a substantial source of whole parasite organisms is a constant source of concern. Thus mechanically transformed schistosomula may be used as alternative for the purpose of high-throughput tools in the field of antischistosomal drugs discovery. This may help for the rapid discovery of urgently needed new drugs that will be useful in the control of schistosmiasis which represent one of the major devastating parasitic infections. Although it is clear from recent publications that subjective measures of NTS viability, motility and phenotype are still the gold standard, none of the automated assessment of phenotype have so far been validated.
Dulbecco’s modified eagle’s medium
Fetal bovine serum
Hanks` balanced salt solution
Inactivated fetal calf serum
Mass drug administration
Minimum essential medium
Medicines for malaria venture
Newly transformed schistosomula
Roswell Park Memorial Institute
Research and training in tropical diseases
Steinmann P, Keiser J, Bos R, Tanner M, Utzinger J. Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk. Lancet Infect Dis. 2006;6(7):411–25.
Gryseels B. Schistosomiasis. Infect Dis Clin North Am. 2012;26(2):383–97.
Ezeamama AE, Friedman JF, Acosta LP, Bellinger DC, Langdon GC, Manalo DL, Olveda RM, Kurtis JD, McGarvey ST. Helminth infection and cognitive impairment among Filipino children. Am J Trop Med Hyg. 2005;72(5):540–8.
Fenwick A, Webster JP, Bosque-Oliva E, Blair L, Fleming FM, Zhang Y, Garba A, Stothard JR, Gabrielli AF, Clements AC, et al. The Schistosomiasis Control Initiative (SCI): rationale, development and implementation from 2002-2008. Parasitology. 2009;136(13):1719–30.
Fenwick A. Praziquantel: do we need another antischistosoma treatment? Future Med Chem. 2015;7(6):677–80.
Knopp S, Stothard JR, Rollinson D, Mohammed KA, Khamis IS, Marti H, Utzinger J. From morbidity control to transmission control: time to change tactics against helminths on Unguja Island, Zanzibar. Acta Trop. 2013;128(2):412–22.
Cupit PM, Cunningham C. What is the mechanism of action of praziquantel and how might resistance strike? Future Med Chem. 2015;7(6):701–5.
Secor WE, Montgomery SP. Something old, something new: is praziquantel enough for schistosomiasis control? Future Med Chem. 2015;7(6):681–4.
Pica-Mattoccia L, Cioli D. Sex- and stage-related sensitivity of Schistosoma mansoni to in vivo and in vitro praziquantel treatment. Int J Parasitol. 2004;34(4):527–33.
Doenhoff MJ, Hagan P, Cioli D, Southgate V, Pica-Mattoccia L, Botros S, Coles G, Tchuem Tchuente LA, Mbaye A, Engels D. Praziquantel: its use in control of schistosomiasis in sub-Saharan Africa and current research needs. Parasitology. 2009;136(13):1825–35.
Pedrique B, Strub-Wourgaft N, Some C, Olliaro P, Trouiller P, Ford N, Pecoul B, Bradol JH. The drug and vaccine landscape for neglected diseases (2000-11): a systematic assessment. Lancet Glob Health. 2013;1(6):e371–379.
Ingram-Sieber K, Cowan N, Panic G, Vargas M, Mansour NR, Bickle QD, Wells TN, Spangenberg T, Keiser J. Orally active antischistosomal early leads identified from the open access malaria box. PLoS Negl Trop Dis. 2014;8(1):e2610.
Keiser J, N'Guessan NA, Adoubryn KD, Silue KD, Vounatsou P, Hatz C, Utzinger J, N'Goran EK. Efficacy and safety of mefloquine, artesunate, mefloquine-artesunate, and praziquantel against Schistosoma haematobium: randomized, exploratory open-label trial. Clin Infect Dis. 2010;50(9):1205–13.
Utzinger J, Xiao SH, Tanner M, Keiser J. Artemisinins for schistosomiasis and beyond. Curr Opin Investig Drugs (London, England: 2000). 2007;8(2):105–16.
Ramirez B, Bickle Q, Yousif F, Fakorede F, Mouries MA, Nwaka S. Schistosomes: challenges in compound screening. Expert Opin Drug Discovery. 2007;2(s1):S53–61.
Loker ES. A comparative study of the life-histories of mammalian schistosomes. Parasitology. 1983;87(Pt 2):343–69.
Peak E, Chalmers IW, Hoffmann KF. Development and validation of a quantitative, high-throughput, fluorescent-based bioassay to detect Schistosoma viability. PLoS Negl Trop Dis. 2010;4(7):e759.
Abdulla MH, Ruelas DS, Wolff B, Snedecor J, Lim KC, Xu F, Renslo AR, Williams J, McKerrow JH, Caffrey CR. Drug discovery for schistosomiasis: hit and lead compounds identified in a library of known drugs by medium-throughput phenotypic screening. PLoS Negl Trop Dis. 2009;3(7):e478.
Keiser J. In vitro and in vivo trematode models for chemotherapeutic studies. Parasitology. 2010;137(3):589–603.
Mansour NR, Bickle QD. Comparison of microscopy and Alamar blue reduction in a larval based assay for schistosome drug screening. PLoS Negl Trop Dis. 2010;4(8):e795.
Colley DG, Bustinduy AL, Secor WE, King CH. Human schistosomiasis. Lancet (London, England). 2014;383(9936):2253–64.
Ross AG, Bartley PB, Sleigh AC, Olds GR, Li Y, Williams GM, McManus DP. Schistosomiasis. N Engl J Med. 2002;346(16):1212–20.
Panic G, Flores D, Ingram-Sieber K, Keiser J. Fluorescence/luminescence-based markers for the assessment of Schistosoma mansoni schistosomula drug assays. Parasit Vectors. 2015;8:624.
Howe S, Zophel D, Subbaraman H, Unger C, Held J, Engleitner T, Hoffmann WH, Kreidenweiss A. Lactate as a novel quantitative measure of viability in Schistosoma mansoni drug sensitivity assays. Antimicrob Agents Chemother. 2015;59(2):1193–9.
Panic G, Vargas M, Scandale I, Keiser J. Activity Profile of an FDA-Approved Compound Library against Schistosoma mansoni. PLoS Negl Trop Dis. 2015;9(7):e0003962.
Marxer M, Ingram K, Keiser J. Development of an in vitro drug screening assay using Schistosoma haematobium schistosomula. Parasit Vectors. 2012;5:165.
Manneck T, Haggenmuller Y, Keiser J. Morphological effects and tegumental alterations induced by mefloquine on schistosomula and adult flukes of Schistosoma mansoni. Parasitology. 2010;137(1):85–98.
Stirewalt MA. Schistosoma mansoni: cercaria to schistosomule. Adv Parasitol. 1974;12:115–82.
Hockley DJ, McLaren DJ. Schistosoma mansoni: changes in the outer membrane of the tegument during development from cercaria to adult worm. Int J Parasitol. 1973;3(1):13–25.
McLaren DJ, Hockley DJ. Schistosoma mansoni: the occurrence of microvilli on the surface of the tegument during transformation from cercaria to schistosomulum. Parasitology. 1976;73(2):169–87.
Tucker MS, Karunaratne LB, Lewis FA, Freitas TC, Liang Y-s. Schistosomiasis. Curr Protoc Immunol/edited by John E Coligan [et al]. 2001;0 19:Unit-19.11.
Samuelson JC, Caulfield JP. The cercarial glycocalyx of Schistosoma mansoni. J Cell Biol. 1985;100(5):1423–34.
Brink LH, McLaren DJ, Smithers SR. Schistosoma mansoni: a comparative study of artificially transformed schistosomula and schistosomula recovered after cercarial penetration of isolated skin. Parasitology. 1977;74(1):73–86.
Ingram K, Ellis W, Keiser J. Antischistosomal activities of mefloquine-related arylmethanols. Antimicrob Agents Chemother. 2012;56(6):3207–15.
Basch PF. Cultivation of Schistosoma mansoni in vitro. I. Establishment of cultures from cercariae and development until pairing. J Parasitol. 1981;67(2):179–85.
de Moraes J, Nascimento C, Yamaguchi LF, Kato MJ, Nakano E. Schistosoma mansoni: in vitro schistosomicidal activity and tegumental alterations induced by piplartine on schistosomula. Exp Parasitol. 2012;132(2):222–7.
Protasio AV, Dunne DW, Berriman M. Comparative study of transcriptome profiles of mechanical- and skin-transformed Schistosoma mansoni schistosomula. PLoS Negl Trop Dis. 2013;7(3):e2091.
Milligan JN, Jolly ER. Cercarial transformation and in vitro cultivation of Schistosoma mansoni schistosomules. J Vis Exp. 2011(54):3191.
Molla E, Giday M, Erko B. Laboratory assessment of the molluscicidal and cercariacidal activities of Balanites aegyptiaca. Asian Pac J Trop Biomed. 2013;3(8):657–62.
Kiros G, Erko B, Giday M, Mekonnen Y. Laboratory assessment of molluscicidal and cercariacidal effects of Glinus lotoides fruits. BMC Res Notes. 2014;7:220.
Albagouri AH, Elegami AA, Koko WS, Osman EE, Dahab MM. In Vitro Anticercarial Activities of some Sudanese Medicinal Plants of the Family Combretaceae. J Forest Products Industries. 2014;3(2):93–9.
dos Santos AF, de Azevedo DPL, dos Santos Mata RC, de Mendonça DIMD, Sant’Ana AEG. The lethality of Euphorbia conspicua to adults of Biomphalaria glabrata, cercaria of Schistosoma mansoni and larvae of Artemia salina. Bioresour Technol. 2007;98(1):135–9.
Mann VH, Morales ME, Rinaldi G, Brindley PJ. Culture for genetic manipulation of developmental stages of Schistosoma mansoni. Parasitology. 2010;137(3):451–62.
Colley DG, Wikel SK. Schistosoma mansoni: simplified method for the production of schistosomules. Exp Parasitol. 1974;35(1):44–51.
Ramalho-Pinto FJ, Gazzinelli G, Howells RE, Mota-Santos TA, Figueiredo EA, Pellegrino J. Schistosoma mansoni: defined system for stepwise transformation of cercaria to schistosomule in vitro. Exp Parasitol. 1974;36(3):360–72.
Howells RE, Ramalho-Pinto FJ, Gazzinelli G, de Oliveira CC, Figueiredo EA, Pellegrino J. Schistosoma mansoni: mechanism of cercarial tail loss and its significance to host penetration. Exp Parasitol. 1974;36(3):373–85.
Stirewalt MA, Minnick DR, Fregeau WA. Definition and collection in quantity of schistosomules of Schistosoma mansoni. Trans R Soc Trop Med Hyg. 1966;60(3):352–60.
Salafsky B, Fusco AC, Whitley K, Nowicki D, Ellenberger B. Schistosoma mansoni: analysis of cercarial transformation methods. Exp Parasitol. 1988;67(1):116–27.
Coultas KA, Zhang SM. In vitro cercariae transformation: comparison of mechanical and nonmechanical methods and observation of morphological changes of detached cercariae tails. J Parasitol. 2012;98(6):1257–61.
Skelly PJ, Shoemaker CB. Induction cues for tegument formation during the transformation of Schistosoma mansoni cercariae. Int J Parasitol. 2000;30(5):625–31.
Stirewalt MA, Uy A. Schistosoma mansoni: cercarial penetration and schistosomule collection in an in vitro system. Exp Parasitol. 1969;26(1):17–28.
Clegg JA, Smithers SR. The effects of immune rhesus monkey serum on schistosomula of Schistosoma mansoni during cultivation in vitro. Int J Parasitol. 1972;2(1):79–98.
Lazdins JK, Stein MJ, David JR, Sher A. Schistosoma mansoni: rapid isolation and purification of schistosomula of different developmental stages by centrifugation on discontinuous density gradients of Percoll. Exp Parasitol. 1982;53(1):39–44.
Mansour NR, Paveley R, Gardner JM, Bell AS, Parkinson T, Bickle Q. High Throughput Screening Identifies Novel Lead Compounds with Activity against Larval, Juvenile and Adult Schistosoma mansoni. PLoS Negl Trop Dis. 2016;10(4):e0004659.
Gold D. Assessment of the viability of Schistosoma mansoni schistosomula by comparative uptake of various vital dyes. Parasitol Res. 1997;83(2):163–9.
Wilson RA. Virulence factors of schistosomes. Microbes Infect. 2012;14(15):1442–50.
Skelly PJ, Alan Wilson R. Making sense of the schistosome surface. Adv Parasitol. 2006;63:185–284.
Peak E, Hoffmann KF. Cross-disciplinary approaches for measuring parasitic helminth viability and phenotype. An Acad Bras Cienc. 2011;83(2):649–62.
Gold D, Flescher E. Influence of mechanical tail-detachment techniques of schistosome cercariae on the production, viability, and infectivity of resultant schistosomula: a comparative study. Parasitol Res. 2000;86(7):570–2.
Nyame AK, Lewis FA, Doughty BL, Correa-Oliveira R, Cummings RD. Immunity to schistosomiasis: glycans are potential antigenic targets for immune intervention. Exp Parasitol. 2003;104(1-2):1–13.
Van der Linden PW, Deelder AM. Schistosoma mansoni: a diamidinophenylindole probe for in vitro death of schistosomula. Exp Parasitol. 1984;57(2):125–31.
Smout MJ, Kotze AC, McCarthy JS, Loukas A. A novel high throughput assay for anthelmintic drug screening and resistance diagnosis by real-time monitoring of parasite motility. PLoS Negl Trop Dis. 2010;4(11):e885.
Lalli C, Guidi A, Gennari N, Altamura S, Bresciani A, Ruberti G. Development and validation of a luminescence-based, medium-throughput assay for drug screening in Schistosoma mansoni. PLoS Negl Trop Dis. 2015;9(1):e0003484.
Emmanuel Mouafo Tekwu is very grateful to the Bill and Melinda Gates Foundation for a two years fellowship in Ghana through the postdoctoral fellowship program at Noguchi Memorial Institute for Medical Research. I would like to thank Miss Deladem Mabel Tettey (Research Assistant, Department of Parasitology, NMIMR) for critical reading of this manuscript.
This work was supported by the Bill and Melinda Gates Foundation under the Postdoctoral and Postgraduate Training in Infectious Diseases Research awarded to the Noguchi Memorial Institute for Medical Research (Global Health Grant number OPP52155). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.
Availability of data and material
EMT conceptualized the topic, developed the review and wrote this manuscript. KMB, AKN, VPB, WA, DB, SK, KBAO reviewed and contributed intellectually for the improvement of the manuscript. All authors read and approved the final version of the manuscript.
The authors declare that they have no competing interests
Consent for publication
Ethics approval and consent to participate